Hyperuricemia was significantly associated with a higher risk of metabolic syndrome compared to the lowest serum uric acid category in Chinese patients receiving lipid-lowering therapy (OR 1.51 in men, OR 2.35 in women).
Cross-Sectional (n=15,401)
Yes
Is elevated serum uric acid associated with metabolic syndrome and cardiovascular disease in Chinese patients on lipid-lowering therapy?
Elevated serum uric acid levels are independently associated with metabolic syndrome, coronary heart disease, and heart failure in middle-aged and elderly Chinese patients receiving lipid-lowering therapy.
Effect estimate: OR 1.51 (men), OR 2.35 (women) (95% CI 1.30-1.74 (men), 2.00-2.75 (women))
BACKGROUND: To explore the association between serum uric acid (SUA) levels, metabolic syndrome (MetS) and cardiovascular disease (CVD) in patients treated with lipid-lowering agents from multiple centers in China. METHOD: We investigated 15,478 participants who had been documented with recorded SUA in the DYSlipidemia International Study which included 25,697 patients, aged 45 years old or older, who were treated with lipid-lowering agents from 122 centers between April 2012 and October 2012. Logistic regression analysis was performed to examine the association between SUA levels, MetS and CVD. RESULT: After adjusting for multi-variables, hyperuricemia (the highest category of SUA level) showed a significantly higher risk of MetS compared to the lowest categoryaccording to NCEP-ATPIII criteria, odds ratio (OR) 1.51, 95 % confidence interval (CI) (1.30,1.74) in men, OR 2.35 95 % CI (2.00,2.75) in women; and according to IDF criteria, OR 1.40 95 % CI (1.20,1.63) in men, OR 1.65 95 % CI (1.41,1.94) in women. In addition, elevated SUA concentration was shown to be associated with coronary heart disease (CHD) (OR 1.26 95 % CI (1.09, 1.45) in men, and OR 1.27, 95 % CI (1.07, 1.50) in women) and heart failure (HF) (OR 1.61 95 % CI (1.15, 2.24) in men, and OR 1.91, 95 % CI (1.29, 2.82) in women). CONCLUSION: Our research suggested a positive association between SUA levels and MetS in Chinese patients receiving lipid-lowering therapy. Elevated SU levels were positively associated independently of measured confounders to CHD and HF.
Tian et al. (Fri,) conducted a cross-sectional in Dyslipidemia (n=15,401). Hyperuricemia (highest category of serum uric acid) vs. Lowest category of serum uric acid was evaluated on Metabolic syndrome (NCEP-ATPIII criteria) (OR 1.51 (men), OR 2.35 (women), 95% CI 1.30-1.74 (men), 2.00-2.75 (women)). Hyperuricemia was significantly associated with a higher risk of metabolic syndrome compared to the lowest serum uric acid category in Chinese patients receiving lipid-lowering therapy (OR 1.51 in men, OR 2.35 in women).